Travere Therapeutics (TVTX) Curent Deferred Tax Liability (2015)

Travere Therapeutics (TVTX) posted Curent Deferred Tax Liability of $15.9 million for Q3 2015, up 82.86% on a QoQ basis from $8.7 million in Q2 2015.

Travere Therapeutics (TVTX) Curent Deferred Tax Liability (2015) Analysis & Trends

Travere Therapeutics' Curent Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $15.9 million for Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Travere Therapeutics	5.21 Bn	5.21 Bn	125.25 Mn	-

Download Data